Pergolide

DB01186ApprovedVet approvedWithdrawnSmall moleculeErgot-derived Dopamine Receptor Agonist

Pergolide is a long-acting dopamine agonist that is uncommonly used for the management of Parkinson's disease, due to the risk for cardiac valvulopathy. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors.

Chemical structure of Pergolide
Mechanism
Curator reviewed
Primary indication
Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease.Curator reviewed · 1 structured indication
Formula / weight
C19H26N2S · 314.488 g/mol (avg)
First approval
Canada, 1991 · United States, 2002
Brand names
  • Permax

Resolves to

Structure
InChIKeyYEHCICAEULNIGD-MZMPZRCHSA-NSMILES[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@@H](CSC)CN2CCC

What you can answer from here — as of September 23, 2026

16Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,269Drug interactionsStructured to mechanism, not free text
Sign in
9Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
2ContraindicationsEach with its own population and attribute set
Sign in
92Marketed productsAcross 4 countries and 8 labellers
Sign in
1ATC codeIncluding every combination product, plus 28 drug categories
Sign in
77+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Pergolide, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account